GlassScriptPhysician profile
Cory Lee Rabe
NPI 1619218302
$8,525.94
in general payments reported to CMS, 2019-2025
19 companies · $2,767 in 2025
The $2,767 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $650 · 2022: $1,767 · 2023: $1,709 · 2024: $1,632 · 2025: $2,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,966 · Consulting Fee: $115 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,966.15 |
| Consulting Fee | $115.00 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,527.35 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,033.66 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $1,002.90 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $977.13 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $664.52 | 2021-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $565.79 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $467.17 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $419.88 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Indivior INC. | $409.28 | 2022-2025 | Perseris, Sublocade |
| E.R. Squibb & Sons, L.L.C. | $372.59 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $316.56 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $204.70 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $144.34 | 2021-2022 | |
| Tris Pharma INC | $119.45 | 2024-2025 | Dyanavel Xr |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $95.30 | 2023-2025 | Trintellix |
| Avanir Pharmaceuticals, INC. | $47.75 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $27.07 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $15.50 | 2025 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Rabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.